A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis

Inclusion Criteria: * Able and willing to provide written informed consent * 18-70 years of age * Males and females with reproductive potential: Willing to use a reliable method of contraception * Diagnosis of ulcerative colitis * Eligible to receive biologic therapy * Disease duration of \>=12 weeks Exclusion Criteria: * Requirement for hospitalization due to severity of ulcerative colitis * Moderate to severe anemia * Any manifestation of ulcerative colitis or other conditions likely to require, in the investigator's judgment, treatment with \>20 mg/day of prednisone, or prednisone equivalent, during the course of the study * Pregnant or lactating * Lack of peripheral venous access * Inability to comply with study protocol * History or presence of contraindicated diseases * Congenital immune deficiency * Active or prior infection with HIV or hepatitis B or C * History of severe systemic bacterial, fungal, viral, or parasitic infections * History of any other opportunistic infections within 12 weeks prior to initiation of study treatment * Received a live attenuated vaccine within 4 weeks prior to screening * Hospitalized within 4 weeks prior to screening * Received any contraindicated therapy within 12 weeks prior to screening